@article {Zhang2020.03.18.20037218, author = {Yanfei Zhang and Ying Hu and Kevin Ho and Dustin N. Hartzel and Vida Abedi and Ramin Zand and Marc S. Williams and Ming Ta M. Lee}, title = {Variants in STAU2 associate with metformin response in a type 2 diabetes cohort: a pharmacogenomics study using real-world electronic health record data}, elocation-id = {2020.03.18.20037218}, year = {2020}, doi = {10.1101/2020.03.18.20037218}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Type 2 diabetes mellitus (T2DM) is a major health and economic burden because of the seriousness of the disease and its complications. Improvements in short- and long-term glycemic control is the goal of diabetes treatment. To investigate the longitudinal management of T2DM at Geisinger, we interrogated the electronic health record (EHR) information and identified a T2DM cohort including 125,477 patients using the Electronic Medical Records and Genomics Network (eMERGE) T2DM phenotyping algorithm. We investigated the annual anti-diabetic medication usage and the overall glycemic control using hemoglobin A1c (HbA1c). Metformin remains the most frequently medication despite the availability of the new classes of anti-diabetic medications. Median value of HbA1c decreased to 7\% in 2002 and since remained stable, indicating a good glycemic management in Geisinger population. Using metformin as a pilot study, we identified three groups of patients with distinct HbA1c trajectories after metformin treatment. The variabilities in metformin response is mainly explained by the baseline HbA1c. The pharmacogenomic analysis of metformin identified a missense variant rs75740279 (Leu/Val) for STAU2 associated with the metformin response. This strategy can be applied to study other anti-diabeticmedications. Such research will facilitate the translational healthcare for better T2DM management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Quality Pilot Fund by Geisinger Health Plan (PI: Ming Ta M. Lee). Regeneron Genetic Center and Geisinger funded the MyCode project.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease contact the corresponding author for data request.T1DMtype 1 diabetes mellitusT2DMtype 2 diabetes mellitusSUsulfonylureasTZDthiazolidinedionesGLP-1Rglucagon-like peptide-1 receptorDPP4dipeptidyl peptidase 4SGLT2sodium-glucose cotransporter-2MACEMajor adverse cardiovascular eventsEHRelectronic health recordSNVssingle nucleotide variantsGWASgenome-wide association study}, URL = {https://www.medrxiv.org/content/early/2020/03/20/2020.03.18.20037218}, eprint = {https://www.medrxiv.org/content/early/2020/03/20/2020.03.18.20037218.full.pdf}, journal = {medRxiv} }